Progression in the LRRK2-Asssociated Parkinson Disease Population.

ABSTRACT:

Importance

Few prospective longitudinal studies have evaluated the progression of Parkinson disease (PD) in patients with the leucine-rich repeat kinase 2 (LRRK2 [OMIM 609007]) mutation. Knowledge about such progression will aid clinical trials.

Objective

To determine whether the longitudinal course of PD in patients with the LRRK2 mutation differs from the longitudinal course of PD in patients without the mutation.

Design, setting, and participants

A prospective comprehensive assessment of a large cohort of patients from 3 sites with LRRK2 PD or with nonmutation PD was conducted from July 21, 2009, to September 30, 2016. All patients of Ashkenazi Jewish ancestry with PD were approached at each site; approximately 80% agreed to an initial visit. A total of 545 patient

SUBMITTER: Saunders-Pullman R 

PROVIDER: S-EPMC5885854 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature